New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
04:55 EDTALKS, ALKS, ANGO, ANGO, SNSS, SNSS, VHS, VHS, IART, IART, OCR, OCR, BKD, BKD, BAX, BAX, ARIA, ARIARBC Capital to host a conference
Healthcare Conference is being held in New York on February 26-27.
News For ALKS;ANGO;SNSS;VHS;IART;OCR;BKD;BAX;ARIA From The Last 14 Days
Check below for free stories on ALKS;ANGO;SNSS;VHS;IART;OCR;BKD;BAX;ARIA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
14:00 EDTBAXBaxter, Halozyme announce favorable FDA panel recommendation on HyQvia
Subscribe for More Information
12:39 EDTBAXFDA panel says HyQvia has favorable benefit-risk ratio, Bloomberg reports
Subscribe for More Information
07:14 EDTALKSAlkermes cuts FY14 adjusted EPS view to 19c-32c, consensus 49c
Subscribe for More Information
07:12 EDTALKSAlkermes reports Q2 adjusted EPS 11c, consensus 14c
Subscribe for More Information
07:10 EDTBAXFDA Blood Products Advisory Committee to hold a meeting
Subscribe for More Information
July 30, 2014
08:08 EDTBAXBaxter announces divestiture of commercial vaccines business to Pfizer for $635M
Baxter International (BAX) announced that it has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer (PFE) for a total cash consideration of $635M, subject to certain adjustments. The sale includes the company’s commercial vaccines business, which is comprised of NeisVac-C, a vaccine which helps protect against meningitis caused by group C meningococcal meningitis, and FSME-IMMUN, which helps protect against tick-borne encephalitis, an infection of the brain transmitted by the bite of ticks infected with the TBE-virus. Both vaccines are currently available outside the United States, primarily in a number of European markets. Baxter continues to explore strategic options, including the potential for partnering or divesting its R&D development programs focused on influenza and Lyme disease. Subject to regulatory approvals and other customary closing conditions, the companies expect to close the transaction by the end of 2014. Baxter expects 2014 vaccines revenues to total approximately $300M and adjusted earnings of approximately 25c per diluted share, including approximately $50M of one-time milestone payments related to the ongoing government collaborations for development of influenza vaccines. Baxter expects the transaction to be modestly dilutive to fourth quarter 2014 adjusted earnings and dilutive to 2015 adjusted earnings by approximately 15c per diluted share.
08:01 EDTBAXPfizer enters into agreement to acquire Baxter's portfolio of marketed vaccines
Subscribe for More Information
07:17 EDTALKSAlkermes announces initiation of ALKS 5461 FORWARD-5 clinical study
Subscribe for More Information
July 23, 2014
18:34 EDTARIAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Fortinet (FTNT), up 7.8%... Hanesbrands (HBI), up 5.4%... 8x8 (EGHT), up 5.1%... Infinera (INFN), up 4.9%... Facebook (FB), reverses and is now trading up 5.1% following second quarter earnings conference call. NOTABLE: Twitter (TWTR), up 1.7%, LinkedIn (LNKD), up marginally, and Yelp (YELP), up 1.6% after Facebook reports second quarter results. ALSO HIGHER: Spectranetics (SPNC), up 7.1% after receiving FDA clearance for atherectomy products, Turbo-Tandem and Turbo Elite... Ariad Pharmaceuticals (ARIA), up 7.1%... Jamba (JMBA), up 3.8% after Engaged Capital reports stake in the company and announced that they had discussions with management. DOWN AFTER EARNINGS: AT&T (T), down 1.2%... Angie's List (ANGI), down 16.4%... Tripadvisor (TRIP), down 11.5%... Orchids Paper (TIS), down 7.4%... Cirrus Logic (CRUS), down 6.6%... Cliffs Natural (CLF), down 1.2%... Teradyne (TER), down 4%. ALSO LOWER: Kandi Technologies (KNDI), down 3.8% after being mentioned negatively in a Seeking Alpha blog post.
16:12 EDTANGOAngioDynamics sees Q1 adjusted EPS 8c-12c, consensus 6c
Subscribe for More Information
16:12 EDTANGOAngioDynamics sees FY15 adjusted EPS 64c-70c, consensus 40c
Subscribe for More Information
16:11 EDTANGOAngioDynamics reports Q4 adjusted EPS 18c, consensus 12c
Subscribe for More Information
13:59 EDTARIAARIAD rises 11.8% to $5.70
10:04 EDTOCROmnicare discloses whistleblower suit in which DOJ declined to intervene
Subscribe for More Information
07:40 EDTOCROmnicare backs FY14 adjusted EPS view of $3.64-$3.72, consensus $3.69
Subscribe for More Information
07:39 EDTOCROmnicare reports Q2 adjusted EPS 91c, consensus 90c
Reports Q2 revenue $1.61B, consensus $1.59B.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use